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Highlights 
•Patients with metastatic colorectal cancer may benefit from radical surgery. 
•Conversion therapy is essential for the possible shift from unresectable to resectable disease. 
•A tailored approach is possible considering patient and disease's factors. 
•Patients presenting with colorectal cancer metastases should be evaluated for multimodal management 
with curative intent. 
 
Abstract 
Colorectal cancer is one of the most common cancers worldwide. In recent years, the survival of patients 
with metastatic disease has improved due to the developments in both medical and surgical care. Patients 
with technically unresectable metastatic disease could benefit from a multidisciplinary approach for their 
possible shift toward a technically resectable condition; the choice of the most effective systemic treatment 
is then crucial to allow conversion to resectability. Systemic conversion therapy may include chemotherapy 
agents’ combinations (fluoropyrimidine, irinotecan and oxaliplatin), with or without targeted agents 
(cetuximab, panitumumab, bevacizumab). The choice of the best treatment option has to be evaluated by 
taking into account each patient's baseline characteristics, biological and pathological information and 
surgical strategy. In particular, the role of some biologic characteristics of the disease, namely the 
mutational status of EGFR-pathway oncogenes, is emerging as an important predictive factor of response 
to anti-EGFR targeted agents. Patients presenting with colorectal cancer metastases should be evaluated 
for multimodal management with curative intent as the appropriate chemotherapy regimen may induce 
tumor shrinkage, conversion to resectability and improved survival 
 




Colorectal cancer (CRC) is one of the leading causes of death from cancer worldwide [1]. In recent decades, 
the survival of patients with metastatic CRC (mCRC), has dramatically improved due to the developments in 
both medical and surgical care [2]. In selected patients, surgery can be included in the treatment plan, as 
the resection of hepatic metastases improves progression-free survival (PFS) and may offer the chance for 
cure in approximately 10–25% of patients [[2], [3],[4], [5], [6], [7], [8]]. 
A thorough evaluation must be carried out to determine the appropriate treatment strategy for every 
patient diagnosed with mCRC. A first analysis should be made to distinguish between patients with 
oncologically non-resectable disease (such as those with multiple sites of metastatic disease), who will 
never be considered for surgery even after responding to medical therapy, from patients with technically 
unresectable metastases, who are regarded as “temporarily” unresectable, and must be carefully evaluated 
in the course of primary systemic treatment for their possible shift (conversion) toward a technically 
resectable condition. Indeed, at present the definition of resectability is solely technical and based on the 
possibility to completely resect all visible metastases leaving an adequately functioning parenchyma [9]. 
This definition of resectability, by excluding all tumor features, implies that each patient must have its 
disease managed by a multidisciplinary team, including medical oncologist, radiologist, interventional 
radiologist, and radiation therapist, where all the specialists involved can correctly define the resectability 
status [10] and reassess the surgical option in case of tumor response. 
Regarding systemic therapy, medical treatment, administered in the case of primarily unresectable disease, 
which is capable of converting the disease to a resectable status, is generally referred to as “conversion 
therapy”. 
In this review we overview the possible therapeutic options for patients with initially unresectable mCRC, 
focusing on individualized approaches to conversion therapy in a multidisciplinary strategy.  
 
Conversion therapy 
Since the 1980s, chemotherapy for CRC has been based on fluoropyrimidine-5-fluorouracil (5-FU), alone or 
in combination with leucovorin (LV). Advances in clinical research have progressively led to the use of 
newer agents, namely irinotecan and oxaliplatin as chemotherapy drugs, and cetuximab, panitumumab, 
bevacizumab, aflibercept and regorafenib as targeted agents [[11], [12], [13], [14]]. 
 
Most of the results in terms of efficacy and tumor shrinkage can be extrapolated from studies that used 
different chemotherapy regimens in the palliative setting. The majority of patients enrolled had an 
“oncologically unresectable” disease, being PFS or overall survival (OS) the primary endpoint. The 
metastasis resection and conversion rates were then evaluated retrospectively and no clear definition of 
resectability was provided. The efficacy of chemotherapeutic associations in doublets or triplets has been 
established [[15], [16], [17], [18], [19], [20], [21]] and afterwards, also the association between 
chemotherapy and monoclonal antibodies has proven to be effective 
[[13], [22], [23], [24], [25], [26],[27], [28], [29], [30], [31], [32], [33], [34], [35], [36]]. The results in terms of 





Table 1Results in terms of overall survival and overall response rate of main phase II and III studies. 
Author Phase N of patients Regimen ORR (%) OS (months) 
De Gramont 2000 III 420 5-FU + leucovorin 21.9 16.2 
5-FU + leucovorin + oxaliplatin 50 14.7 
Giacchetti 2000 III 200 chrono5-FU + leucovorin 16 19.9 
chrono5-FU + leucovorin + oxaliplatin 53 19.4 
Douillard 2000 III 387 5-FU + leucovorin 22 14.1 
5-FU + leucovorin + irinotecan 35 17.4 
Saltz 2000 III 683 5-FU + leucovorin+ irinotecan 50 14.8 
5-FU + leucovorin 28 12.6 
irinotecan 29 12 
Goldberg 2004 III 795 IFL 31 15 
IROX 35 17.4 
FOLFOX 45 19.5 
Colucci 2005 III 360 FOLFIRI 31 15 
FOLFOX4 34 14 
Van Cutsem 2009 III 1198 FOLFIRI + cetuximab 46.9 (59.3)a 19.9 (24.9)a 
FOLFIRI 38.7 (43.2)a 18.6 (21)a 
Bokemeyer 2009 III 337 FOLFOX4 + cetuximab 46 (61)a NA 
FOLFOX4 36 (37)a NA 
Folprecht 2010 III 111 FOLFOX6 + cetuximab 68 = 
FOLFIRI + cetuximab 57 = 
Maughan 2011 III 1630a FOLFOX/XELOX 57 17.9 
FOLFOX/XELOX + cetuximab 64 17 
Ye 2013 III 138a FOLFIRI/FOLFOX + cetuximab 57.1 30.9 
FOLFIRI/FOLFOX 29.4 21 
Douillard 2010 III 1183 FOLFOX4 + panitumumab 55a 23.9a 
FOLFOX4 48a 19.7a 
Leone 2013 III 49 (35)a XELOX + panitumumab 54 (87,5 DCRa) 21.9 
Schwartzberg 2012 II 245a FOLFOX6 + panitumumab 58 NR 
FOLFOX6 + bevacizumab 54 25.4 
Hurwitz 2004 III 813 IFL + bevacizumab 44.8 20.3 
IFL 34.8 15.6 
Saltz 2008 III 1401 FOLFOX/XELOX + bevacizumab 38 21.3 
FOLFOX/XELOX + placebo 38 19.9 
Van Cutsem 2009 EA 1914 FOLFOX/XELOX/XELIRI/5-FU + bevacizumab NA 22.7 
Wong 2011 II 46 CAPOX + bevacizumab 78 NA 
Souglakos 2002 II 31 Irinotecan + oxaliplatin + 5-FU/LV 58.1 NR 
Falcone 2002 II 42 Irinotecan + oxaliplatin + 5-FU/LV 69 26.5 
Masi 2004 II 32 FOLFOXIRI 72 28.4 
Souglakos 2006 III 285 FOLFIRI 33.6 19.5 
FOLFOXIRI 43 21.5 
Falcone 2007 III 244 FOLFIRI 34 16.7 
FOLFOXIRI 60 22.6 
Garufi 2010 II 43 chronoIFLO + cetuximab 79.1 37 (stim) 
Assennat 2011 II 42 FOLFIRINOX + cetuximab 80.9 (83.3)a 24.7 (NR)a 
Saridaki 2012 II 30a FOLFOXIRI + cetuximab 70 30.3 
Fornaro 2013 II 37a FOLFOXIRI + panitumumab 89 NR 
Loupakis 2013 III 508 FOLFIRI + bevacizumab 53 NA 
FOLFOXIRI + bevacizumab 64 NA 
Gruenberger 2013 III 80 mFOLFOX6 + bevacizumab 61.5 NA 
FOLFOXIRI + bevacizumab 80.5 NA 
Heinemann 2013 III 592a FOLFIRI + cetuximab 62 28.5 
FOLFIRI + bevacizumab 57 25 
Bruera 2012 II 50a FirBFox 84 23 
ORR, overall response rate; OS, overall survival; 5-FU, 5-fluorouracil; EA, expanded access; NA, not assessed; NR, not reached. 
a  KRAS wt population. 
 
Several studies have investigated the use of different schemes in the specific setting of conversion therapy; 
all these trials have explored the association of chemotherapy with monoclonal antibodies (MoAbs). 
The phase II BOXER trial evaluated bevacizumab, a MoAb against VEGF, in association with a capecitabine 
and oxaliplatin (CAPOX) chemotherapy regimen in patients ineligible for upfront surgery, which resulted in 
an ORR of 78%. The conversion rate in this trial reached 40%, with 12 out of 30 patients judged to be 
resectable after treatment [35]. 
In the randomized phase II trial OLIVIA, bevacizumab was evaluated in association with mFOLFOX6 or 
FOLFOXIRI. The response rate (RR) was higher in the FOLFOXIRI-bevacizumab arm (80.5% vs. 61.5% in the 
FOLFOX arm; p = 0.061). Although this value did not reach statistical significance, radical (R0) resection rate 
was significantly higher in the FOLFOXIRI-bevacizumab arm (48.8% vs. 23.1%; p = 0.017) [27]. 
Other studies evaluated the use of anti-EGFR monoclonal antibodies in the conversion setting. As will be 
further discussed below, during the clinical development of these drugs (cetuximab particularly) the 
mutational status of KRAS was recognized as a predictive marker of response to therapy. As a result, in 
older studies, patients were unselected and the evaluation in the KRAS wild type (KRASwt) population was 
performed retrospectively. 
The CELIM phase II randomized trial compared the association of cetuximab with FOLFIRI and FOLFOX6 in 
patients with non-resectable liver metastases. The difference between the two groups, in terms of RR, was 
not significant. Tumor response, evaluated in a retrospective analysis, was significantly higher in patients 
with KRASwt tumors (70% vs. 41%, p = 0.008). R0 resection was possible in 38% of patients in FOLFOX6-
cetuximab arm and 30% of patients in FOLFIRI-cetuximab arm. According to the retrospective review, 
resectability rates increased from 32% at baseline to 60% after chemotherapy (p < 0.0001), regardless of 
the regimen used [37]. 
In a recent phase II randomized trial, patients with KRASwt synchronous non-resectable liver-limited 
metastases were assigned to receive chemotherapy alone (FOLFIRI or FOLFOX) or in combination with 
cetuximab. The ORR was 57.1% in the association arm and 29.4% in the chemotherapy only arm (p = 0.001), 
with a R0 resection rate of 25.7% and 7.4%, respectively (p = 0.04) [36]. 
The impact of panitumumab as a part of a conversion strategy has been investigated in the MetaPan phase 
II study, in which panitumumab was associated with a doublet chemotherapy containing capecitabine and 
oxaliplatin (XELOX). In patients with KRASwt tumors, the ORR was 60%, with a conversion rate of 42% of 
initially unresectable patients being able to undergo curative surgery [30]. 
 
Individualized approach 
As we have outlined, different regimens translate into different treatment options, the choice of which has 
to be evaluated by taking into account each patient's baseline characteristics, previous therapies, 
pathological information and surgical strategy. 
What do we know before starting systemic treatment? 
The major baseline characteristics of the patient that influence the treatment choice are age and 
performance status (PS). 
As a result of increasing life expectancy, the incidence of CRC in older patients is progressively rising. 
Whether to give treatment to this large population or not should not be based on temporal age only, but 
also on functional status, social situation and pathologic/pharmacologic factors [38]. 
A determination of the frailty by additional assessment tools routinely used by geriatricians, such as 
activities of daily living (ADL) [39], is mandatory and can predict which patients are more likely to develop 
adverse events [[40], [41]]. 
Several studies, mainly retrospective series, suggest that both surgical and medical treatments in this 
population are as safe and effective as in the younger population [[42], [43], [44]], but data on an 
integrated conversion strategy are lacking. The current evidence supports treatment for fit elderly patients, 
who can achieve similar outcomes to that of younger patients [45]. 
Although not routinely tested in clinical practice, some genetic alterations have been correlated to standard 
chemotherapy agents, both for response to treatment or development of toxicities. In particular, ERCC1 
polymorphisms, thymidine phosphorylase, or thymidylate synthase expression are associated with the 
efficacy of oxaliplatin or 5-FU [[46], [47], [48]]. Efficacy of irinotecan treatment could be associated with 
topoisomerase I overexpression [[49], [50]]. As for toxicity, dihydropyrimidine dehydrogenase deficiency 
and UGT1A1 polymorphism have been correlated with the onset of severe, unexpected toxicity respectively 
to fluoropyrimidines and irinotecan [[51], [52], [53]]. More recently, the individuation of specific alterations 
leading to defective DNA repair has paved the way for using well-known alkylating agents, such as 
dacarbazine, in CRC patients [54]. 
Other important baseline information includes biologic characteristics of the disease, namely the 
mutational status of KRAS and other relevant oncogenes. 
In the past few years, the KRAS mutational status has been validated as a predictive factor of response to 
the anti-EGFR antibodies cetuximab and panitumumab [[55], [56], [57], [58], [59]]. 
Additional genotyping of KRAS downstream genes could be a strategy for selecting patients eligible for anti-
EGFR therapy; several retrospective analyses, preclinical models and patients’ series have shown how 
mutations of certain markers downstream of KRAS could impact on the response to anti-EGFR MoAbs 
[[60], [61], [62], [63], [64]]. The resistance to cetuximab in KRAS-mutant mCRC cannot be reverted either in 
the presence of ADCC activation mediated by leinalidomide [[65], [66]]. 
In the retrospective analysis by De Roock et al., it was demonstrated that patients with mutations in one of 
the genes BRAF, NRAS, or PIK3CA exon 20 show a lower RR compared to wild type patients in a KRASwt 
population treated with cetuximab [67]. 
Undoubtedly, the EGFR pathway is currently one of the most relevant research topics because of its 
implications in both upfront selection of patients prior to targeted treatment and monitoring of secondary 
resistance [[63], [68], [69]]. In clinical practice, mutational status of KRAS on exon 2 has been the only 
predictive marker routinely tested for years, but recent analysis on large randomized trials have shown that 
a larger screening for mutations on KRAS exon 3 or 4, NRAS exon 2, 3, or 4, or BRAF exon 15 is required 
prior to using anti-EGFR MoAb therapy. Among patients with wtKRAS on exon 2, 17–31% might harbor 
other RAS mutations that interfere with response to targeted agents; in this population the addition of 
cetuximab or panitumumab in the treatment plan might have a detrimental effect. On the contrary, all-RAS 
wild type patients show a significant improvement in both OS and PFS. Similarly, ORR is improved in all-RAS 
wild type patients treated with anti-EGFR MoAb therapy, making a deeper molecular screening crucial in 
the context of a conversion therapy [[25], [70], [71], [72], [73], [74]]. 
A second issue when using anti-EGFR MoAbs is choosing the right chemotherapy complement; based on 
the results of the COIN and Nordic VII trials [[75], [76]] it was suggested that oxaliplatin-based regimens 
might not represent an optimal backbone therapy. However, preclinical data and the final results of the 
PRIME and OPUS trials contradict this hypothesis [[77], [78], [79]]. 
This discordance may be due to the different fluoropyrimidine administration rather than a negative 
interaction between cetuximab and oxaliplatin; although it has never been formally demonstrated, 
cetuximab could be more effective with infusional 5FU than with bolus 5FU alone or capecitabine 
[[29], [80]]. 
What happens during systemic treatment? 
It is now established that chemotherapy may induce liver damage; in particular oxaliplatin has been linked 
to sinusoidal wall disruption, resulting in sinusoidal obstruction syndrome (SOS) [[81], [82], [83]]. Similarly, 
irinotecan can induce a type of non-alcoholic fatty liver disease known as steatohepatitis [[84], [85]]. 
Conversely, no specific hepatic toxicity has been linked to MoAbs [86] and, in particular, a protective role of 
bevacizumab against the development of SOS has been demonstrated in several publications 
[[87], [88], [89]]. 
Chemotherapy-associated liver injuries may cause bleeding during surgery or poor liver reserve which both 
result in increased postoperative morbidity and mortality rates [[90], [91]]. 
It is therefore necessary to closely monitor tumor shrinkage (for example with a TC-scan every 8 weeks) 
and plan the timing of the resection to coincide with completion of the minimum number of chemotherapy 
courses required to achieve resectability, as it has been demonstrated that prolonged chemotherapy does 
not improve the pathologic response but just increases the risk of hepatotoxicity [92]. 
Regarding response to therapy, in order to maximize the disease downsizing to facilitate resection, the 
choice of the drug combination regimen is critical to the success of the curative strategy. A strong 
relationship between tumor RR and resection rates has been demonstrated in mCRC treated with 
chemotherapy [93]. Furthermore, pathological analysis after systemic treatment may reveal prognostic 
information, such as tumor regression rate. The scoring system is based on the presence of fibrosis 
overgrowing on tumor cells, rather than the increase of necrosis. Patients experiencing major histological 
tumor regression showed an improved 3-year disease free survival (DFS) compared with those who had 
partial or no regression, resulting in a better 5-year OS rate. As for the chemotherapy regimen used as a 
neoadjuvant systemic treatment, histological tumor regression was most common among oxaliplatin-
treated patients and it was associated with a better clinical outcome [94]. 
One of the major concerns is related to the disappearance of metastases as a consequence of neoadjuvant 
therapy. It has been demonstrated that viable tumor cells persist in up to 80% of metastases after complete 
radiological response [[95],[96]]. This poses the surgeon in a puzzling situation; it has been suggested that 
in such cases liver resection should include all the sites of a tumor detected prior to systemic treatment 
[97]. 
Conclusions 
We have overviewed the current evidence for mCRC treatment, focusing on the individualized approach to 
resectability. Tailoring the treatment strategy is now possible and, as we have shown in our review, 
patients presenting with CRC metastases should be evaluated for multimodal management with curative 
intent [22]. Clinical studies specifically designed for potentially resectable patients in the context of a 
conversion strategy are required; more homogeneous criteria of resectability should be therefore used 
across the studies. We suggest that, in the case of hepatic disease, unresectability is defined as ≥1 of the 
following: no possibility of upfront R0/R1 resection of all hepatic lesions, <30% estimated residual liver 
after resection, or disease in contact with major vessels of the remnant liver. 
Drawing evidence-based conclusions about the best regimen to use is sometimes difficult; only a small 
number of clinical trials are specifically designed for conversion systemic treatment. Data are generally 
retrieved from larger phase III studies where the primary endpoint is PFS or OS and patient population 
often varies. In addition, data on metastasectomies available in the literature mainly regard hepatic lesions, 
not taking into account the recent progress that has been made in thoracic and abdominal surgery 
[[98], [99], [100]]. 
The introduction of targeted agents has led to the definition of new paradigms in clinical oncology. The final 
goal will be to maximize the therapeutic index of novel agents, while at the same time providing the actual 
translation of individualized therapy into the clinical setting. 
Even though the identification of genetic markers may drive the treatment strategy and improve outcomes, 
the binary correlation between a mutated cancer gene and the response to a targeted therapy is proving 
more difficult than expected. This may be due to the intratumor heterogeneity [101] and the complexity of 
the signaling pathways in an individual cancer. The importance of selecting different molecular predictive 
markers prior to treatment is progressively emerging [70]. 
At the same time, it must be taken into account that a large percentage of patients do not express any 
“druggable” alteration. This might be due to different factors; absence of “driving” genetic alterations, 
activation of distinct pathways at the same time or absence of efficacy-proven targeted drugs. Maximizing 
the impact of systemic treatment in this population is furthermore challenging as it involves the field of 
early drug development, hitting new druggable pathways or combining targeted agents. 
The preferred choice of MoAb for a conversion therapy remains debatable. A direct comparison between 
cetuximab and bevacizumab in association with FOLFIRI, in the multicenter, randomized phase III FIRE-3 
trial showed a 62% ORR in FOLFIRI-cetuximab arm vs. 57% in FOLFIRI-bevacizumab arm (p = 0.183). No 
difference in PFS was found (10.3 vs. 10.4 months for cetuximab and bevacizumab arm, respectively). The 
difference in OS, however, reached a statistically significant value in favor of cetuximab (28.8 vs. 25.0 
months; p = 0.0164) [28]. Similarly, the comparison of bevacizumab or panitumumab with mFOLFOX6 in a 
phase II randomized trial showed similar ORR (54% for bevacizumab and 58% for panitumumab), PFS (10.1 
vs. 10.9 months) and OS (25.4 months vs. not yet reached) [34]. 
These results regarding OS, especially in the all-RAS wild type population, seem to favor a frontline 
treatment with anti-EGFR MoAbs, but a clearer evidence on ORR and resection rate in potentially 
resectable patients is still needed; results from the CALGB/SWOG 80405 trial are pending, and randomized 
trials or ad hoc analysis in the conversion setting might finally answer the question whether the addition of 
a specific MoAb can improve the resection rate in all-RAS wild type population. 
For RAS or BRAF mutated patients, triplet chemotherapy and combinations with bevacizumab represent 
two rationale alternatives on the basis of high response rates and tumor shrinkage [102], but their efficacy 
in conversion setting has not yet been demonstrated in specifically designed studies. 
Whether combination of triplets and targeted agents should be considered another step forward, requires 
further confirmation; in our opinion this field of research might be particularly promising in the setting of 
conversion therapy. 
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